ethotoin
Trade name: peganone
Approved
Apr 22, 1957
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. Ethotoin inhibits nerve impulses in the motor cortex by lowering sodium ion influx, limiting tetanic stimulation. Ethotoin is used for the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures. Ethotoin is marketed as Peganone by Ovation. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Timeline
Indications
Approved for
Mechanism of action
- Sodium channel alpha subunitBLOCKER
Sodium channel alpha subunit blocker
- Sodium channel protein type 1 subunit alpha (SCN1A) ↗
- Sodium channel protein type 5 subunit alpha (SCN5A) ↗
- Sodium channel protein type 4 subunit alpha (SCN4A) ↗
- Sodium channel protein type 7 subunit alpha (SCN7A) ↗
- Sodium channel protein type 2 subunit alpha (SCN2A) ↗
- Sodium channel protein type 9 subunit alpha (SCN9A) ↗
- Sodium channel protein type 3 subunit alpha (SCN3A) ↗
- Sodium channel protein type 11 subunit alpha (SCN11A) ↗
- Sodium channel protein type 8 subunit alpha (SCN8A) ↗
- Sodium channel protein type 10 subunit alpha (SCN10A) ↗
- Sodium channel protein type I alpha subunit
- Sodium channel protein type V alpha subunit
- Sodium channel protein type IV alpha subunit
- Sodium channel protein type VII alpha subunit
- Sodium channel protein type IX alpha subunit
- Sodium channel protein type II alpha subunit
- Sodium channel protein type III alpha subunit
- Sodium channel protein type XI alpha subunit
- Sodium channel protein type VIII alpha subunit
- Sodium channel protein type X alpha subunit
- Sodium channel alpha subunits; brain (Types I, II, III)
Approval history
- approvedPriority reviewApr 22, 1957
Chemistry & pharmacology
SMILES
CCN1C(=O)NC(C1=O)C2=CC=CC=C2- Mol. weight
- 204.2252 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaEthotoin ↗
- NCATS46QG38NC4U ↗
- ChEMBLCHEMBL1095 ↗
Also known as
- 1-ethyl-2,5-dioxo-4-phenylimidazolidine
- 1-ethyl-2,5-dioxo-4-phenylimidazolidine
- 2,4-imidazolidinedione, 3-ethyl-5-phenyl-
- 3-ethyl-5-phenyl-2,4-imidazolidinedione
- 3-ethyl-5-phenyl-2,4-imidazolidinedione
- (+-)-3-ethyl-5-phenylhydantoin
- (+-)-3-ethyl-5-phenylhydantoin
- 3-ethyl-5-phenylhydantoin
- 3-ethyl-5-phenylhydantoin
- 3-ethyl-5-phenylimidazolidin-2,4-dione
- 3-ethyl-5-phenylimidazolidin-2,4-dione
- 3-ethyl-5-phenyl-imidazolidine-2,4-dione
- 3-ethyl-5-phenyl-imidazolidine-2,4-dione
- abbott brand of ethotoin
- accenon
- ethotoin
- ethotoin
- ethotoin
- ethotoin
- ethotoin
- ethotoin
- ethotoin
- ethotoin
- ethotoin
- ethotoin
- ethotoïne
- ethotoïne
- ethotoinum
- ethotoinum
- etotoina
- etotoina
- peganone
- peganone
- peganone
- peganone
- peganone